通心络对急性冠状动脉综合征患者血浆C-反应蛋白和内皮素-1的影响

Effect of Tongxinluo capsule on the plasma C-reactive protein and endothelin-1 in acute coronary syndrome patients

目的探讨通心络胶囊对急性冠状动脉综合征（ACS）患者血浆C-反应蛋白（CRP）和内皮素-1（ET-1）的影响。方法将100例ACS患者随机分为常规组和通心络组（常规治疗＋通心络胶囊），观察治疗前及第7、14天血浆CRP和ET-1的变化。结果与治疗前相比，第7、14天通心络组血浆CRP和ET-1水平均显著下降，差异有统计学意义（P〈0．05、P〈0．01）；而常规组仅第14天有显著变化，与治疗前比较差异有统计学意义（P〈0．05）。通心络组CRP和ET-1水平与常规组比较差异有统计学意义（P〈0．01）。结论通心络可能通过抑制CRP和ET-1减少血管内膜的炎症反应等途径改善血管内皮功能，从而达到对血管内皮的保护作用。

Objective To study the effect of Tongxinluo on the plasma C-reactive protein （CRP） and endothelin-1 （ ET-1 ） in acute coronary syndrome （ACS） patients. Methods 100 patients with ACS were randomly divided into conventional therapy group and treatment group （ conventional therapy ＋ Tongxinluo gelatin capsule ）. The changes of CRP and ET-1 in the first day,7th and 14th day were observed. Results In the treatment group,CRP and ET-1 were significantly decreased in the 7th and 14th day（ P 〈 0.05 ,P 〈 0.01 ） , and there was significant decrease only in the 14th day （P 〈 0.05）in the conventional therapy group. CRP and ET-1 levels in the treatment group were significantly different as compared with conventional thereapy group （ P 〈 0.01 ）. Conclusion Tongxinluo capsule may protect blood vessel endothelium through inhibiting CRP and ET-1 to decrease the inflammatory response of endangium.